MTOR and breast carcinoma: Our findings suggest that metabolic plasticity (high mTOR activity and the overexpression of at least two alternative metabolic pathway–related enzymes) could be a subtype-independent risk factor in breast cancers, certain lung tumors rhabdomyosarcomas, and pheochromocytomas [128, 207, 334, 335].